Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ADVANZ PHARMA Corp. Limited

https://www.advanzpharma.com/

Latest From ADVANZ PHARMA Corp. Limited

Kyorin Pharma To Shut Down US Subsidiary ActivX

Kyorin Pharma is to end operations at its US subsidiary ActivX 18 years since its acquisition. Although the California firm’s kinase-probing technology has contributed to Kyorin’s R&D, the Japanese firm acknowledged limits to future applicability in the development of candidate compounds.

Business Strategies Research & Development

Eisai To Shut Down H3 In Global R&D Restructuring

Eisai has decided to shut down its US oncology research operation H3 by September in the course of restructuring its global R&D organization. The majority of H3 employees will be laid off as Eisai Inc. and new organization DHBL absorb its functions and assets. Meanwhile another Japanese pharma firm, Astellas, builds up its US R&D footprint.

Business Strategies Restructuring

Tech Transfer Roundup: Amylyx Goes Pipeline Hunting While Seeking US Approval Of ALS Candidate

Amylyx is funding research at the Sunnybrook Research Institute to investigate Bax and Bak inhibition in neurodegenerative disease. Repertoire looks into HPV+ cancer with Memorial Sloan Kettering.

Tech Transfer Round-Up Deals

Following Positive IIb Study Data, Can 180 Life Sciences Clear The Next Regulatory Hurdle?

180 Life Sciences has found that adalimumab can effectively treat nodule hardness and size in Dupuytren’s disease during a Phase IIb study. But, the company’s CEO Jim Woody tells Generics Bulletin, regulators in the UK and US have requested more information before they will press on with authorization.

Regulation Biosimilars
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • ADVANZ PHARMA
    • ADVANZ PHARMA Corp. Limited
    • Amdipharm Mercury Limited
    • Concordia Healthcare Corp.
    • Concordia International Corp.
    • Concordia Laboratories, Inc.
    • Concordia Pharmaceuticals, Inc.
    • Covis Pharma S.à.r.l, Covis Injectables, S.à.r.l
    • Correvio Pharma Corp
UsernamePublicRestriction

Register